Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial

Neurotherapeutics. 2021 Apr;18(2):868-877. doi: 10.1007/s13311-020-00973-9. Epub 2021 Jan 19.

Abstract

Gadolinium (Gd)-contrast MRI for reliable detection of blood-brain barrier (BBB) breakdown is widely used in neuromyelitis optica spectrum disorder (NMOSD) attack. Nonetheless, little is known about the predictive role of gadolinium-enhancing lesion in prognosis of NMOSD attack. The aim of this work is to investigate the predictive value of persistently Gd-enhanced lesions to medium-term outcome after attack. Data for this analysis came from an ongoing prospective cohort study (CLUE). NMOSD patients with acute attack were enrolled from January 2019 to March 2020. All patients underwent Gd-contrast MRI at baseline and 1 month, and disability was assessed by Expanded Disability Status Scale (EDSS). Primary outcome was EDSS improvement from baseline to month 6. Multiple logistic regression identified predictors for poor recovery of NMOSD attack. Forty-one participants were analyzed, of which 21 patients had persistently Gd-enhancing lesions. Patients in no enhancement (NE) group showed a significant shift in 6-month EDSS distributions compared with those in persistent enhancement (PE) group (p = 0.005). Poor recovery rate of the PE group was higher than that of the NE group at 6 months (p = 0.033). In patients with aquaporin-4-positive, first-attack, transverse myelitis or in a high-dose steroid treatment subgroup, the improvement of EDSS scores in the PE group was still less compared with that in the NE group (p < 0.05). The presence of persistently Gd-enhancing lesion appears to be associated with poor recovery after attack (OR = 5.473, p = 0.014). Our study found that persistently gadolinium-enhancing lesion is a poor prognosis predictor after NMOSD attack. Trial registration ID: NCT04106830.

Keywords: MRI; NMOSD; acute attack; clinical trial; prognosis.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • China / epidemiology
  • Female
  • Follow-Up Studies
  • Gadolinium / metabolism*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Magnetic Resonance Imaging / trends*
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Neuromyelitis Optica / diagnostic imaging*
  • Neuromyelitis Optica / drug therapy
  • Neuromyelitis Optica / epidemiology
  • Neuromyelitis Optica / metabolism*
  • Neuroprotective Agents / therapeutic use
  • Predictive Value of Tests
  • Prognosis
  • Prospective Studies

Substances

  • Biomarkers
  • Neuroprotective Agents
  • Gadolinium
  • Methylprednisolone

Associated data

  • ClinicalTrials.gov/NCT04106830